ASSOSIATION BETWEEN ENDOTHELIAL AND PLATELET DERIVED MICROPARTICLES AND VENOUS THROMBOSIS IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA (MM) AND NON HODGKIN LYMPHOMA (NHL) - PRELIMINARY REPORT
(Abstract release date: 05/19/16)
EHA Library. Usnarska-Zubkiewicz L. 06/09/16; 134863; PB1963
Prof. Dr. Lidia Usnarska-Zubkiewicz
Contributions
Contributions
Abstract
Abstract: PB1963
Type: Publication Only
Background
Multiple myeloma and non-Hodgkin lymphoma and its treatment are frequently complicated by development of venous thromboembolism (VTE). The incidence of thrombotic complications dramatically raise after highly prothrombotic therapeutic regimens e.g. with thalidomide and lenalidomide in MM.
Aims
The aim of this study was to examine whether procoagulant microparticles (MPs) derived from endothelial cells (EMPs) and platelets (PMPs) constitute an enhanced risk for venous thrombosis.
Methods
We studied 22 patients (pts) without history of VTE, 10/12 F/M, aged 24-84 years. There were 13 pts of MM (9 cases of IgG, 2 of IgA, 1 IgM and 1 non secretory MM) and 9 pts with nHL (5 cases of DLBCL, 2 anaplastic T cell lymphoma and 2 FL).All patients underwent routine coagulation tests. Flow-cytometry was used for quantification of endothelial cell (CD133+) microparticles (EMPs) and platelet (CD61+) microparticles (PMPs). In all pts ultrasound examination of venous system of the lower extremities was performed. Both deep and superficial veins of both limbs were evaluated. Conventional and Doppler imagination, as well as elastography and options to detect microcalcifications (micropure) were used.
Results
The ultrasound examination revealed the presence of vein thrombosis in 11 pts (group I, n = 11). Five out of 11 pts with bilateral lesions in VSM (vena saphena magna, great saphenous vein) and lower leg veins or bilateral in VSM only comprised subgroup Ia. Six pts with unilateral blood clots in VSM formed group Ib. Thrombosis was observed in 7 pts with MM and 4 with nHL, and bilateral thrombotic lesions were demonstrated in 2 MM and 3 nHL pts. The remaining 11 pts showed no thrombosis (group II).The mean percentage of EMPs (CD133+) was 1,04±1,03, and it did not significantly differ between thrombotic (group I) and non-thrombotic patients (group II) 1,22±1,24 vs 0,85±0,77, p=0,406), but there was a trend for increased EMPs in the subgroup Ia (1,37±1,17). The percentage of PMPs (CD61+) was 13,14±4,68 and similar in all studied groups: group I 12,82±3,28 vs group II 13,45±5,92 (p=0,759), including subgroup Ia (11,80±2,32).Mean plasma fibrinogen (FBG) concentration was 3,65±1,85 g/L and did not significantly differ in MM and nHL patients with and without thrombosis (4,06±1,90 vs. 3,24±0,1,80 g/L, p=0,309). But FBG level in subgroup Ia was found to be significantly higher than that in the remaining patients (5,07±2,45 vs. 3,23±1,48, p=0,047). Mean D-dimer level was 2,59±4,70mg/L, and there was not significantly different in patients with and without thrombosis (4,01±6,40 vs. 1,16±0,97 mg/L, p=0,159), however D-dimer was elevated in subgroup Ia in comparison with that in group II (2,52±1,29 vs. 1,16±0,97 mg/L, p=0,034).
Conclusion
Venous thrombosis was confirmed in 11 of 22 patients with newly diagnosed patients with MM and n-HL. In patients with many thrombotic lesions there was a trend for elevated activity of endothelial cells (EMPs), but not platelets (PMPs).
Session topic: E-poster
Keyword(s): Endothelial microparticle, Multiple myeloma, Non-Hodgkin's lymphoma, Thrombosis
Type: Publication Only
Background
Multiple myeloma and non-Hodgkin lymphoma and its treatment are frequently complicated by development of venous thromboembolism (VTE). The incidence of thrombotic complications dramatically raise after highly prothrombotic therapeutic regimens e.g. with thalidomide and lenalidomide in MM.
Aims
The aim of this study was to examine whether procoagulant microparticles (MPs) derived from endothelial cells (EMPs) and platelets (PMPs) constitute an enhanced risk for venous thrombosis.
Methods
We studied 22 patients (pts) without history of VTE, 10/12 F/M, aged 24-84 years. There were 13 pts of MM (9 cases of IgG, 2 of IgA, 1 IgM and 1 non secretory MM) and 9 pts with nHL (5 cases of DLBCL, 2 anaplastic T cell lymphoma and 2 FL).All patients underwent routine coagulation tests. Flow-cytometry was used for quantification of endothelial cell (CD133+) microparticles (EMPs) and platelet (CD61+) microparticles (PMPs). In all pts ultrasound examination of venous system of the lower extremities was performed. Both deep and superficial veins of both limbs were evaluated. Conventional and Doppler imagination, as well as elastography and options to detect microcalcifications (micropure) were used.
Results
The ultrasound examination revealed the presence of vein thrombosis in 11 pts (group I, n = 11). Five out of 11 pts with bilateral lesions in VSM (vena saphena magna, great saphenous vein) and lower leg veins or bilateral in VSM only comprised subgroup Ia. Six pts with unilateral blood clots in VSM formed group Ib. Thrombosis was observed in 7 pts with MM and 4 with nHL, and bilateral thrombotic lesions were demonstrated in 2 MM and 3 nHL pts. The remaining 11 pts showed no thrombosis (group II).The mean percentage of EMPs (CD133+) was 1,04±1,03, and it did not significantly differ between thrombotic (group I) and non-thrombotic patients (group II) 1,22±1,24 vs 0,85±0,77, p=0,406), but there was a trend for increased EMPs in the subgroup Ia (1,37±1,17). The percentage of PMPs (CD61+) was 13,14±4,68 and similar in all studied groups: group I 12,82±3,28 vs group II 13,45±5,92 (p=0,759), including subgroup Ia (11,80±2,32).Mean plasma fibrinogen (FBG) concentration was 3,65±1,85 g/L and did not significantly differ in MM and nHL patients with and without thrombosis (4,06±1,90 vs. 3,24±0,1,80 g/L, p=0,309). But FBG level in subgroup Ia was found to be significantly higher than that in the remaining patients (5,07±2,45 vs. 3,23±1,48, p=0,047). Mean D-dimer level was 2,59±4,70mg/L, and there was not significantly different in patients with and without thrombosis (4,01±6,40 vs. 1,16±0,97 mg/L, p=0,159), however D-dimer was elevated in subgroup Ia in comparison with that in group II (2,52±1,29 vs. 1,16±0,97 mg/L, p=0,034).
Conclusion
Venous thrombosis was confirmed in 11 of 22 patients with newly diagnosed patients with MM and n-HL. In patients with many thrombotic lesions there was a trend for elevated activity of endothelial cells (EMPs), but not platelets (PMPs).
Session topic: E-poster
Keyword(s): Endothelial microparticle, Multiple myeloma, Non-Hodgkin's lymphoma, Thrombosis
Abstract: PB1963
Type: Publication Only
Background
Multiple myeloma and non-Hodgkin lymphoma and its treatment are frequently complicated by development of venous thromboembolism (VTE). The incidence of thrombotic complications dramatically raise after highly prothrombotic therapeutic regimens e.g. with thalidomide and lenalidomide in MM.
Aims
The aim of this study was to examine whether procoagulant microparticles (MPs) derived from endothelial cells (EMPs) and platelets (PMPs) constitute an enhanced risk for venous thrombosis.
Methods
We studied 22 patients (pts) without history of VTE, 10/12 F/M, aged 24-84 years. There were 13 pts of MM (9 cases of IgG, 2 of IgA, 1 IgM and 1 non secretory MM) and 9 pts with nHL (5 cases of DLBCL, 2 anaplastic T cell lymphoma and 2 FL).All patients underwent routine coagulation tests. Flow-cytometry was used for quantification of endothelial cell (CD133+) microparticles (EMPs) and platelet (CD61+) microparticles (PMPs). In all pts ultrasound examination of venous system of the lower extremities was performed. Both deep and superficial veins of both limbs were evaluated. Conventional and Doppler imagination, as well as elastography and options to detect microcalcifications (micropure) were used.
Results
The ultrasound examination revealed the presence of vein thrombosis in 11 pts (group I, n = 11). Five out of 11 pts with bilateral lesions in VSM (vena saphena magna, great saphenous vein) and lower leg veins or bilateral in VSM only comprised subgroup Ia. Six pts with unilateral blood clots in VSM formed group Ib. Thrombosis was observed in 7 pts with MM and 4 with nHL, and bilateral thrombotic lesions were demonstrated in 2 MM and 3 nHL pts. The remaining 11 pts showed no thrombosis (group II).The mean percentage of EMPs (CD133+) was 1,04±1,03, and it did not significantly differ between thrombotic (group I) and non-thrombotic patients (group II) 1,22±1,24 vs 0,85±0,77, p=0,406), but there was a trend for increased EMPs in the subgroup Ia (1,37±1,17). The percentage of PMPs (CD61+) was 13,14±4,68 and similar in all studied groups: group I 12,82±3,28 vs group II 13,45±5,92 (p=0,759), including subgroup Ia (11,80±2,32).Mean plasma fibrinogen (FBG) concentration was 3,65±1,85 g/L and did not significantly differ in MM and nHL patients with and without thrombosis (4,06±1,90 vs. 3,24±0,1,80 g/L, p=0,309). But FBG level in subgroup Ia was found to be significantly higher than that in the remaining patients (5,07±2,45 vs. 3,23±1,48, p=0,047). Mean D-dimer level was 2,59±4,70mg/L, and there was not significantly different in patients with and without thrombosis (4,01±6,40 vs. 1,16±0,97 mg/L, p=0,159), however D-dimer was elevated in subgroup Ia in comparison with that in group II (2,52±1,29 vs. 1,16±0,97 mg/L, p=0,034).
Conclusion
Venous thrombosis was confirmed in 11 of 22 patients with newly diagnosed patients with MM and n-HL. In patients with many thrombotic lesions there was a trend for elevated activity of endothelial cells (EMPs), but not platelets (PMPs).
Session topic: E-poster
Keyword(s): Endothelial microparticle, Multiple myeloma, Non-Hodgkin's lymphoma, Thrombosis
Type: Publication Only
Background
Multiple myeloma and non-Hodgkin lymphoma and its treatment are frequently complicated by development of venous thromboembolism (VTE). The incidence of thrombotic complications dramatically raise after highly prothrombotic therapeutic regimens e.g. with thalidomide and lenalidomide in MM.
Aims
The aim of this study was to examine whether procoagulant microparticles (MPs) derived from endothelial cells (EMPs) and platelets (PMPs) constitute an enhanced risk for venous thrombosis.
Methods
We studied 22 patients (pts) without history of VTE, 10/12 F/M, aged 24-84 years. There were 13 pts of MM (9 cases of IgG, 2 of IgA, 1 IgM and 1 non secretory MM) and 9 pts with nHL (5 cases of DLBCL, 2 anaplastic T cell lymphoma and 2 FL).All patients underwent routine coagulation tests. Flow-cytometry was used for quantification of endothelial cell (CD133+) microparticles (EMPs) and platelet (CD61+) microparticles (PMPs). In all pts ultrasound examination of venous system of the lower extremities was performed. Both deep and superficial veins of both limbs were evaluated. Conventional and Doppler imagination, as well as elastography and options to detect microcalcifications (micropure) were used.
Results
The ultrasound examination revealed the presence of vein thrombosis in 11 pts (group I, n = 11). Five out of 11 pts with bilateral lesions in VSM (vena saphena magna, great saphenous vein) and lower leg veins or bilateral in VSM only comprised subgroup Ia. Six pts with unilateral blood clots in VSM formed group Ib. Thrombosis was observed in 7 pts with MM and 4 with nHL, and bilateral thrombotic lesions were demonstrated in 2 MM and 3 nHL pts. The remaining 11 pts showed no thrombosis (group II).The mean percentage of EMPs (CD133+) was 1,04±1,03, and it did not significantly differ between thrombotic (group I) and non-thrombotic patients (group II) 1,22±1,24 vs 0,85±0,77, p=0,406), but there was a trend for increased EMPs in the subgroup Ia (1,37±1,17). The percentage of PMPs (CD61+) was 13,14±4,68 and similar in all studied groups: group I 12,82±3,28 vs group II 13,45±5,92 (p=0,759), including subgroup Ia (11,80±2,32).Mean plasma fibrinogen (FBG) concentration was 3,65±1,85 g/L and did not significantly differ in MM and nHL patients with and without thrombosis (4,06±1,90 vs. 3,24±0,1,80 g/L, p=0,309). But FBG level in subgroup Ia was found to be significantly higher than that in the remaining patients (5,07±2,45 vs. 3,23±1,48, p=0,047). Mean D-dimer level was 2,59±4,70mg/L, and there was not significantly different in patients with and without thrombosis (4,01±6,40 vs. 1,16±0,97 mg/L, p=0,159), however D-dimer was elevated in subgroup Ia in comparison with that in group II (2,52±1,29 vs. 1,16±0,97 mg/L, p=0,034).
Conclusion
Venous thrombosis was confirmed in 11 of 22 patients with newly diagnosed patients with MM and n-HL. In patients with many thrombotic lesions there was a trend for elevated activity of endothelial cells (EMPs), but not platelets (PMPs).
Session topic: E-poster
Keyword(s): Endothelial microparticle, Multiple myeloma, Non-Hodgkin's lymphoma, Thrombosis
{{ help_message }}
{{filter}}